Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.

PloS one - 1 Jan 2011

O'Brien Thomas R, Everhart James E, Morgan Timothy R, Lok Anna S, Chung Raymond T, Shao Yongwu, Shiffman Mitchell L, Dotrang Myhanh, Sninsky John J, Bonkovsky Herbert L, Pfeiffer Ruth M

Abstract excerpt

BACKGROUND: Genetic variation in IL28B and other factors are associated with sustained virological response (SVR) after pegylated-interferon/ribavirin treatment for chronic hepatitis C (CHC). Using data from the HALT-C Trial, we developed a model to predict a patient's probability of SVR based on IL28B genotype and clinical variables. METHODS: HALT-C enrolled patients with advanced CHC who had failed previous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Demography

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 21760886
DOI: 10.1371/journal.pone.0020904
PMCID: PMC3132753

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.PMID 21760886Read ↗

IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.Semantic proximity Read ↗

Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.Semantic proximity Read ↗

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Semantic proximity Read ↗

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.Semantic proximity Read ↗

Role of IL28B for chronic hepatitis C treatment toward personalized medicine.Semantic proximity Read ↗

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.Semantic proximity Read ↗

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.Semantic proximity Read ↗

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.Semantic proximity Read ↗

IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection.Semantic proximity Read ↗

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.Semantic proximity Read ↗

IL28B single nucleotide polymorphisms in the treatment of hepatitis C.Semantic proximity Read ↗

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.